An Italy-based KOL covers treatment patterns in acute lymphoblastic leukemia (ALL) across pediatric and adult patients, including frontline therapy, consolidation, maintenance, and management of relapsed or refractory disease. They discuss use and sequencing of key drug classes such as chemotherapy, asparaginase formulations, TKIs in Ph+ ALL, monoclonal antibodies, and CAR?T therapy, with differences by age, Ph status, and disease burden. The KOL also addresses clinical decision drivers such as minimal residual disease (MRD), transplant eligibility, toxicity considerations, and how evolving molecular insights are shaping treatment choices.

This interview was conducted on July 18, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.